These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 34751411)

  • 1. PIK3CA mutation affects the proliferation of colorectal cancer cells through the PI3K-MEK/PDK1-GPT2 pathway.
    Chen W; Dai G; Qian Y; Wen L; He X; Liu H; Gao Y; Tang X; Dong B
    Oncol Rep; 2022 Jan; 47(1):. PubMed ID: 34751411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer.
    Hao Y; Samuels Y; Li Q; Krokowski D; Guan BJ; Wang C; Jin Z; Dong B; Cao B; Feng X; Xiang M; Xu C; Fink S; Meropol NJ; Xu Y; Conlon RA; Markowitz S; Kinzler KW; Velculescu VE; Brunengraber H; Willis JE; LaFramboise T; Hatzoglou M; Zhang GF; Vogelstein B; Wang Z
    Nat Commun; 2016 Jun; 7():11971. PubMed ID: 27321283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quadruple-editing of the MAPK and PI3K pathways effectively blocks the progression of KRAS-mutated colorectal cancer cells.
    Wang Z; Kang B; Gao Q; Huang L; Di J; Fan Y; Yu J; Jiang B; Gao F; Wang D; Sun H; Gu Y; Li J; Su X
    Cancer Sci; 2021 Sep; 112(9):3895-3910. PubMed ID: 34185934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aspirin has a better effect on PIK3CA mutant colorectal cancer cells by PI3K/Akt/Raptor pathway.
    Chen Z; Wang C; Dong H; Wang X; Gao F; Zhang S; Zhang X
    Mol Med; 2020 Jan; 26(1):14. PubMed ID: 32000660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PIK3CA mutations-mediated downregulation of circLHFPL2 inhibits colorectal cancer progression via upregulating PTEN.
    Chong X; Chen J; Zheng N; Zhou Z; Hai Y; Chen S; Zhang Y; Yu Q; Yu S; Chen Z; Bao W; Quan M; Chen ZS; Zhan Y; Gao Y
    Mol Cancer; 2022 May; 21(1):118. PubMed ID: 35619132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers.
    Temraz S; Mukherji D; Shamseddine A
    Int J Mol Sci; 2015 Sep; 16(9):22976-88. PubMed ID: 26404261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PDK1 Mediates
    Sambandam V; Frederick MJ; Shen L; Tong P; Rao X; Peng S; Singh R; Mazumdar T; Huang C; Li Q; Pickering CR; Myers JN; Wang J; Johnson FM
    Clin Cancer Res; 2019 Jun; 25(11):3329-3340. PubMed ID: 30770351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
    Coussy F; El Botty R; Lavigne M; Gu C; Fuhrmann L; Briaux A; de Koning L; Dahmani A; Montaudon E; Morisset L; Huguet L; Sourd L; Painsec P; Chateau-Joubert S; Larcher T; Vacher S; Melaabi S; Salomon AV; Marangoni E; Bieche I
    J Hematol Oncol; 2020 Feb; 13(1):13. PubMed ID: 32087759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of WNT/β-catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations.
    Park YL; Kim HP; Cho YW; Min DW; Cheon SK; Lim YJ; Song SH; Kim SJ; Han SW; Park KJ; Kim TY
    Int J Cancer; 2019 Jan; 144(2):389-401. PubMed ID: 29978469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation.
    Fang DD; Zhang CC; Gu Y; Jani JP; Cao J; Tsaparikos K; Yuan J; Thiel M; Jackson-Fisher A; Zong Q; Lappin PB; Hayashi T; Schwab RB; Wong A; John-Baptiste A; Bagrodia S; Los G; Bender S; Christensen J; Vanarsdale T
    PLoS One; 2013; 8(6):e67258. PubMed ID: 23826249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA‑126‑3p suppresses HeLa cell proliferation, migration and invasion, and increases apoptosis via the PI3K/PDK1/AKT pathway.
    Ichikawa R; Kawasaki R; Iwata A; Otani S; Nishio E; Nomura H; Fujii T
    Oncol Rep; 2020 Apr; 43(4):1300-1308. PubMed ID: 32323808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual inhibitors of RAF-MEK-ERK and PI3K-PDK1-AKT pathways: Design, synthesis and preliminary anticancer activity studies of 3-substituted-5-(phenylamino) indolone derivatives.
    Yu Z; Chen Z; Su Q; Ye S; Yuan H; Kuai M; Lv M; Tu Z; Yang X; Liu R; Hu G; Li Q
    Bioorg Med Chem; 2019 Mar; 27(6):944-954. PubMed ID: 30777660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PIK3CA-mutated melanoma cells rely on cooperative signaling through mTORC1/2 for sustained proliferation.
    Silva JM; Deuker MM; Baguley BC; McMahon M
    Pigment Cell Melanoma Res; 2017 May; 30(3):353-367. PubMed ID: 28233937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.
    Engelman JA; Chen L; Tan X; Crosby K; Guimaraes AR; Upadhyay R; Maira M; McNamara K; Perera SA; Song Y; Chirieac LR; Kaur R; Lightbown A; Simendinger J; Li T; Padera RF; García-Echeverría C; Weissleder R; Mahmood U; Cantley LC; Wong KK
    Nat Med; 2008 Dec; 14(12):1351-6. PubMed ID: 19029981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. XIAP-targeting drugs re-sensitize PIK3CA-mutated colorectal cancer cells for death receptor-induced apoptosis.
    Ehrenschwender M; Bittner S; Seibold K; Wajant H
    Cell Death Dis; 2014 Dec; 5(12):e1570. PubMed ID: 25501831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA‑363‑3p inhibits cell proliferation and induces apoptosis in retinoblastoma cells via the Akt/mTOR signaling pathway by targeting PIK3CA.
    Ma X; Jin L; Lei X; Tong J; Wang R
    Oncol Rep; 2020 May; 43(5):1365-1374. PubMed ID: 32323827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chromatin remodeling gene AT-rich interactive domain-containing protein 1A suppresses gastric cancer cell proliferation by targeting PIK3CA and PDK1.
    Zhang Q; Yan HB; Wang J; Cui SJ; Wang XQ; Jiang YH; Feng L; Yang PY; Liu F
    Oncotarget; 2016 Jul; 7(29):46127-46141. PubMed ID: 27323812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combine MEK inhibition with PI3K/mTOR inhibition exert inhibitory tumor growth effect on KRAS and PIK3CA mutation CRC xenografts due to reduced expression of VEGF and matrix metallopeptidase-9.
    E J; Xing J; Gong H; He J; Zhang W
    Tumour Biol; 2015 Feb; 36(2):1091-7. PubMed ID: 25326806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor suppressor miR-193a-3p enhances efficacy of BRAF/MEK inhibitors in BRAF-mutated colorectal cancer.
    Hiraide S; Takahashi M; Yoshida Y; Yamada H; Komine K; Ishioka C
    Cancer Sci; 2021 Sep; 112(9):3856-3870. PubMed ID: 34288281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.
    Vitiello PP; Cardone C; Martini G; Ciardiello D; Belli V; Matrone N; Barra G; Napolitano S; Della Corte C; Turano M; Furia M; Troiani T; Morgillo F; De Vita F; Ciardiello F; Martinelli E
    J Exp Clin Cancer Res; 2019 Jan; 38(1):41. PubMed ID: 30691487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.